ibandronate sodium hydrate / Generic mfg. - LARVOL DELTA

Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions. (PubMed, Pharmaceutics) - "Clinical evidence is summarized for oral semaglutide, cyanocobalamin, unfractionated heparin, ibandronate, and investigational peptide products...Overall, SNAC reliably enhances permeation in vitro and in vivo, yet the resulting oral bioavailability remains low and variable and is strongly dependent on payload, formulation, and gastrointestinal conditions. Long-term safety and the clinical relevance of recent preclinical microbiome findings remain important areas for future investigation."

Journal • Review • Gastrointestinal Disorder • Metabolic Disorders

Burning Questions: Oral Ulceration Secondary to Improper Bisphosphonate Administration in Advanced Dementia. (PubMed, Geriatrics (Basel)) - "Denosumab was substituted in view of the patient's dysphagia and cognitive status...Ibandronate-related cases are rarely reported, likely reflecting prescribing frequency rather than lower risk... Presence of dysphagia and cognitive status should be assessed before and during oral bisphosphonate therapy. New oral pain, ulceration or facial swelling should prompt oral examination and medication review, with alternative antiresorptive agents considered when oral administration is impaired."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Gastrointestinal Disorder • Oncology • Osteoporosis • Pain • Rheumatology

Repeated romosozumab with short-term ibandronate sequencing in high-risk osteoporosis: a retrospective single-center cohort study. (PubMed, JBMR Plus) - "All patients received eldecalcitol 0.75 μg daily. Repeated courses were accompanied by longitudinal improvements in recorded skeletal measures and bone turnover markers. Because this was an uncontrolled retrospective study and patient-level baseline data for the 19 patients who discontinued were unavailable in the analytical dataset, the findings should be considered descriptive and hypothesis-generating."

Journal • Retrospective data • Cardiovascular • Endocrine Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (clinicaltrials.gov) - P4 | N=52 | Recruiting | Sponsor: National Taiwan University Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2026 ➔ Aug 2026 | Trial primary completion date: Mar 2030 ➔ Aug 2030

Enrollment open • Head-to-Head • Trial initiation date • Trial primary completion date • Osteoporosis • Rheumatology

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Khyber Medical University Peshawar | Recruiting ➔ Completed

Trial completion • Osteoporosis • Rheumatology

Direct effects of taxane-based chemotherapy on bone mass and bone strength in an experimental animal model, and mitigation by ibandronate (ASBMR 2026) - No abstract available

Preclinical

Atypical Femoral Fracture With Low Cumulative Ibandronate Exposure: A Case Challenging Duration-Based Risk Assumptions (ASBMR 2026) - No abstract available

Clinical • Musculoskeletal Diseases • Orthopedics

The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price. (PubMed, Osteoporos Int) - "With sufficient price reductions, biosimilar denosumab is a dominant strategy across varying levels of baseline fracture risk. Biosimilar denosumab's superior efficacy and favorable safety profile compared to bisphosphonates, along with anticipated price declines, support its potential as a first-line therapy for women with PMO at high-risk of fracture in the US."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

ZAMBONI: Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Kelly Fitzgerald, MD | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Global burden of pain in malignant bone tumors: a meta-analysis of severity and health outcomes. (PubMed, Front Oncol) - "Treatments involved External Beam Radiotherapy (EBRT) in single or multi-fractions, BMAs (zoledronic acid, ibandronate, pamidronate, denosumab), and radiopharmaceuticals (Radium-223, Strontium-89, Samarium-153) either alone or in combination. The variance in results was minimal, and the majority of the studies were classified as fair to good quality according to the Jadad and GRADE evaluations. Radiotherapy, BMAs, and radiopharmaceuticals, either singly or in tandem, are well-tolerated for managing pain and preventing SREs in patients with malignant bone tumors, thereby providing patients with various ways to enhance their quality of life."

HEOR • Journal • Retrospective data • Review • Oncology • Osteosarcoma • Pain • Solid Tumor

Evaluation of 161Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone Metastases. (PubMed, Mol Pharm) - "Early human data confirmed its safety and therapeutic potential. The complementary use of [68Ga]Ga/[161Tb]Tb-DOTA-IBA enables a unified diagnostic-therapeutic platform for the management of bone metastases, providing an innovative, targeted treatment option capable of improving both quality of life and survival in patients with advanced skeletal disease."

Journal • Oncology • Pain • Solid Tumor

Effectiveness and safety of antiresorptive drugs in patients with systemic sclerosis-a retrospective monocentric study. (PubMed, EULAR Rheumatol Open) - "One patient developed stage 1 osteonecrosis of the jaw (ONJ) under ibandronate. Subgroup analysis suggests that parenteral administration, particularly denosumab, may offer superior efficacy. Gastrointestinal adverse effects were mild and consistent with published rates in the general population, whereas ONJ could be more relevant than in the general population."

Journal • Retrospective data • Gastrointestinal Disorder • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

Ibandronate Use in Osteoporotic Vertebral Fractures: A Retrospective Clinical Study Integrated with Exploratory Network Pharmacology and Cross-Cohort Transcriptomic Analysis. (PubMed, Biomedicines) - "However, these findings should not be interpreted as direct mechanistic evidence of ibandronate-specific molecular activity or clinical efficacy. Larger prospective studies integrating clinical, radiological, and mechanistic approaches are required to clarify the biological and clinical relevance of these observations."

Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology

The CFIm25/FDPs axis orchestrates protective mitophagy in macrophages to attenuate myocardial infarction. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Pharmacological inhibition of FDPS using ibandronate attenuated PINK1/Parkin pathway activation, reduced LC3-II accumulation, and suppressed mitophagy, demonstrating that FDPS is functionally required for CFIm25 deficiency-induced mitophagic responses. Collectively, these findings support a model in which CFIm25 deficiency promotes FDPS-dependent activation of PINK1/Parkin-mediated mitophagy, thereby enhancing mitochondrial quality control and limiting inflammation. This study identifies a previously unrecognized CFIm25/FDPS signaling axis regulating macrophage mitophagy following MI and highlights its potential therapeutic relevance in ischemic heart injury."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Infarction • NUDT21

Comparing Bisphosphonates and Denosumab for Hypercalcemia Treatment : A Propensity-Matched Cohort Study (ENDO 2026) - "Adults (≥18 years) with documented hypercalcemia (≥2 serum calcium measurements ≥12.0 mg/dL) who received bisphosphonates (zoledronic acid, pamidronate, or ibandronate) or denosumab within 7 days of hypercalcemia diagnosis were included. Bisphosphonates demonstrated superior effectiveness in achieving normocalcemia compared to denosumab, with faster calcium correction and higher response rates. While both agents had similar overall hypocalcemia rates, denosumab was associated with a significantly higher risk of severe hypocalcemia. These findings support bisphosphonates as first-line therapy for hypercalcemia, with careful monitoring for severe hypocalcemia when denosumab is used."

Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Cell Carcinoma • Renal Disease

FRONTLINE BORTEZOMIB–MELPHALAN–PREDNISONE IN TRANSPLANT-INELIGIBLE ELDERLY MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER REAL-WORLD STUDY (EHA 2026) - "Patients with progression, received lenalidomide–dexamethasone (96%) or botezomib- lenalidomide-dexamethasone (4%) as second line therapy. Supportive care included bisphosphonates in all patients (zoledronic acid: 76%, ibandronate: 24%) and systematic antiviral prophylaxis...Summary/Conclusion In this real-world cohort of transplant-ineligible elderly MM patients, frontline VMP achieved meaningful response rates and durable survival despite a high burden of comorbidities. Toxicity was manageable, supporting VMP as an effective and feasible frontline option, particularly in resource-constrained settings."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Endocrine Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • Myelodysplastic Syndrome • Orthopedics • Plasmacytoma • Renal Disease • Transplantation

Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer. (PubMed, Int J Clin Pharmacol Ther) - "Clodronate was most effective in reducing pathological fractures, zoledronate was superior in controlling hypercalcemia, and ibandronate demonstrated the best safety profile. Further clinical studies are warranted to clarify the comparative advantages of each bisphosphonate and support individualized treatment decisions."

Journal • Retrospective data • Breast Cancer • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Oncology • Solid Tumor

Do Glucagon-like peptide-1 Based Therapies Increase the Risk of Adverse Effects in Those Taking Oral Bisphosphonates for Osteoporosis? (EULAR 2026) - "Methods This study included patients 18 years and older treated with oral bisphosphonates (alendronate, risendronate, ibandronate) and GLP-1 receptor agonists (semaglutide, exenatide, dulaglutide, liraglutide, lixisenatide) or dual acting GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (tirzepatide)...Propensity score matching was used for the age at index event, sex, race/ethnicity, and confounding variables such as metabolic calcium disorders, traumatic injury, systemic lupus erythematosus, rheumatoid arthritis, and medications known to cause hypocalcemia such as cinacalcet and foscarnet...Further research should be conducted with a larger population and for a longer duration to confirm that there is no significant change in risk of vertebral compression fracture, atypical femur fracture, or osteonecrosis of the jaw even while on drug holiday from oral bisphosphonate. Image(s), graphic(s), or table(s)"

Adverse events • Acute Kidney Injury • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Conjunctivitis • Diabetes • Endocrine Disorders • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Ocular Infections • Ocular Inflammation • Ophthalmology • Orthopedics • Osteoporosis • Renal Disease • Rheumatoid Arthritis • Rheumatology • Scleritis • Systemic Lupus Erythematosus • Urticaria • Uveitis

ZAMBONI: A phase II study of zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases previously treated with immune checkpoint inhibitors. (ASCO 2026) - P2 | "Investigator-choice BMA may include zoledronic acid, pamidronate, ibandronate, or denosumab, will be administered at a standard dose/interval starting within 30 days of cycle 1, day 1 (C1D1), and continued until criteria for discontinuation of BMA or removal from study are met. The primary endpoint is 12-month landmark progression-free survival and will be evaluated in patients with RECIST-measurable disease at baseline; key secondary endpoints include overall survival, rate of skeletal-related events, and rate of osteonecrosis of the jaw and will be measured in all patients. Clinical trial information: NCT07043608."

Checkpoint inhibition • P2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Denosumab and risk of Type 2 Diabetes Risk Among Patients with Osteoporosis: A Retrospective Cohort Study. (PubMed, Endocr Pract) - "Among patients with osteoporosis, IV bisphosphonates were associated with a lower risk of incident T2D compared with denosumab. These findings suggest potential metabolic benefits of IV bisphosphonates and support the need for prospective studies to validate these observations."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus

Renal Outcomes and Dosage Considerations Associated with Bisphosphonate Use: A Systematic Review of Randomized Clinical Trials. (PubMed, Res Sq) - "Further, random effects model (100% (-0.01)) was performed due to high level of heterogeneity and it indicated that ibandronate 27.93%; alendronate 28.58%; risedronate 27.80% and zoledronate 15.69%. Conclusion The evidence from this review suggests that the bisphosphonates are generally well-tolerated with ten trials registering no drug-related withdrawals and other studies showing only very negligible withdrawals due to adverse effects. Even though bisphosphonates are safer to use in compromised renal function i.e., > 30ml/min/1.73m 2 , more cohort studies are required to identify bisphosphonates effects in end stage renal disease (eGFR < 15ml/min/1.73m 2 )."

Clinical • Journal • Chronic Kidney Disease • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Transplantation

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions. (PubMed, Front Oncol) - "BPs - including clodronate, pamidronate, ibandronate, and zoledronic acid - as well as denosumab have shown efficacy and safety in the treatment of bone metastases secondary to breast cancer. There is an unmet need for improvement of SREs. Bone-forming agents should be seriously considered for this purpose."

Journal • Review • Breast Cancer • Oncology • Oral Cancer • Palliative care • Solid Tumor

Combined Post-operative Denosumab and Oral Bisphosphonate Therapy Following Resection of Spinal Giant Cell Tumor: A Case Report. (PubMed, J Orthop Case Rep) - "Postoperatively, denosumab therapy was continued for 6 months, and the patient was simultaneously commenced on oral bisphosphonate therapy (weekly alendronate followed by monthly ibandronate). This report demonstrates the feasibility of combining post-operative denosumab and oral bisphosphonate therapy as an adjuvant strategy for high-risk SGCT when wide surgical margins are not achievable. By targeting different cellular pathways involved in tumor biology, this approach may provide complementary tumor control, thereby reducing the risk of recurrence."

Journal • Back Pain • Giant Cell Tumor of Bone • Lumbar Back Pain • Musculoskeletal Pain • Oncology • Osteosarcoma • Pain • Solid Tumor

ZAMBONI: Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Kelly Fitzgerald, MD | Trial completion date: Sep 2029 ➔ Feb 2030 | Initiation date: Sep 2025 ➔ May 2026 | Trial primary completion date: Sep 2028 ➔ Feb 2029

Checkpoint inhibition • Trial completion date • Trial initiation date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis. (PubMed, Pharmacoecon Open) - "Biosimilar denosumab was estimated to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid at a WTP threshold of $150,000/QALY gained and compared with risedronate at a threshold of $100,000/QALY gained. As a lower-cost alternative to reference denosumab, biosimilar denosumab may enhance patient access to effective PMO treatment in the USA."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology